2021
Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States. JAMA Dermatology 2021, 157: 59-65. PMID: 33146688, PMCID: PMC7643047, DOI: 10.1001/jamadermatol.2020.4102.Peer-Reviewed Original ResearchConceptsMerkel cell carcinomaBirth cohort effectsCell carcinomaIncidence rateCalendar periodBirth cohortPatient ageNew casesCohort effectsEnd Results Program databaseCross-sectional retrospective studyLongitudinal cohort studyHigh incidence rateAge-adjusted ratesRisk factor exposureRecent birth cohortsCohort studyCarcinoma incidenceRetrospective studyNeuroendocrine cancerAge effectsProgram databaseCohort analysisMAIN OUTCOMECarcinoma
2016
Palliative Care for Pancreatic and Periampullary Cancer
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surgical Clinics Of North America 2016, 96: 1415-1430. PMID: 27865285, PMCID: PMC5119929, DOI: 10.1016/j.suc.2016.07.012.Peer-Reviewed Original ResearchConceptsMost patientsPalliative careGastric outlet obstructionRelief of painPancreatic cancer patientsAdvanced diseaseLocalized diseaseMultimodality therapyCeliac plexusOutlet obstructionPeriampullary cancerObstructive jaundiceCancer patientsPancreatic cancerPalliative techniquesPatientsCommon endpointCancerDiseaseReliefCareCare triangleFamily goalsJaundicePainLonger Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 18-26. PMID: 24351782, PMCID: PMC4061284, DOI: 10.1097/coc.0000000000000022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyCohort StudiesDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansInduction ChemotherapyMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsProportional Hazards ModelsRetrospective StudiesSex FactorsTime FactorsTreatment OutcomeConceptsAdvanced pancreatic cancerCycles of chemotherapyOverall survivalInduction chemotherapyPancreatic cancerMedian overall survivalRole of chemotherapyTreatment of LAPCUnresectable stage 3Better survival outcomesBetter overall survivalCombination of chemotherapyJohns Hopkins HospitalSensitization of tumorsConsolidative chemoradiationSubsequent chemoradiationCombination chemotherapyCumulative incidenceProspective studySurvival outcomesStandard treatmentDisease progressionChemoradiationRetrospective analysisChemotherapy
2014
A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors
Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH. A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. Annals Of Surgery 2014, 259: 204-212. PMID: 23673766, PMCID: PMC4048026, DOI: 10.1097/sla.0b013e31828f3174.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsStaging systemSimple prognostic toolNeuroendocrine tumorsPrognostic toolStage IFive-year overall survival rateNonfunctional pancreatic neuroendocrine tumorsMain staging systemsAJCC stage ITumor staging systemOverall survival rateAmerican Joint CommitteeSingle-institution seriesKi-67 labelingPrognostic factorsSurvival prognosticationSingle institutionJoint CommitteeMultivariate analysisNatural historyComparison of reportsPatientsNeoplasmsSurvival
2011
Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas
Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology 2011, 24: 1237-1247. PMID: 21552209, PMCID: PMC3155013, DOI: 10.1038/modpathol.2011.74.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaE-cadherin expressionPancreatic adenocarcinomaDuctal adenocarcinomaIndependent predictorsPoor outcomeCox proportional hazards regression modelingProportional hazards regression modelingPancreatic cancer outcomesWorse median survivalResectable pancreatic adenocarcinomaMinority of patientsKaplan-Meier analysisE-cadherin statusMedian survivalSurgical resectionWorse prognosisCancer outcomesSubgroup analysisPathological factorsPatient outcomesCell adhesion moleculeMortality riskTissue microarrayPartial lossPresence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3493-3499. PMID: 21537863, PMCID: PMC3166423, DOI: 10.1245/s10434-011-1745-9.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaResection marginsTransection marginR0 resectionIntraepithelial neoplasiaPanIN lesionsPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsPancreatic resection marginPancreatic transection marginPresence of PanINOverall median survivalIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsSurgical margins
2009
Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research 2009, 69: 3681-3688. PMID: 19351817, PMCID: PMC2669837, DOI: 10.1158/0008-5472.can-09-0015.Peer-Reviewed Original ResearchConceptsPancreatic cancerCigarette smokingGenetic Mutations AssociatedSomatic mutationsPancreatic cancer genomeCigarette smokersSmoking accountsPancreatic carcinomaDiscovery screenSmokersCarcinomaSmokingCancerMutations AssociatedMutational patternsAdenocarcinomaDriver genesPancreasCigarettesMore mutationsMutationsNonsynonymous mutationsNonsmokersPrevious studiesIndividuals